A Phase 1, Double-Blind, Active- and Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Bupivacaine (Primary)
- Indications Anaesthesia; Dental pain; Postoperative pain
- Focus Pharmacokinetics
- Sponsors Pacira BioSciences
Most Recent Events
- 17 Mar 2025 Status changed from recruiting to completed.
- 04 Jun 2024 Planned End Date changed from 30 Jul 2024 to 25 Dec 2024.
- 04 Jun 2024 Planned primary completion date changed from 30 Jul 2024 to 25 Dec 2024.